Novocure Reports Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
NovoCure Ltd. (NVCR) PT Raised to $24 at H.C. Wainwright
July 26, 2024 6:48 AM EDTH.C. Wainwright analyst Emily Bodnar raised the price target on NovoCure Ltd. (NASDAQ: NVCR) to $24.00 (from $22.00) while maintaining a Neutral rating.
The analyst comments "Optune growth in glioblastoma (GBM) fueled by impressive France launch; additional launches could occur in 2025. Novocure announced 2Q24 financial results and provided a corporate update on July 25. Sales in 2Q24 were $150.4M, roughly an 8.6% increase from 1Q24. We note that 1Q24 revenues... More
